ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 580,37
-0,38%
Dow Jones
39 127,80
0,04%
DAX
18 149,68
-0,08%
Brent Oil
84,92
0,53%
Bitcoin
61 247,29
0,71%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. C4 Therapeutics Inc (CCCC)

  7. C4 Therapeutics Inc (CCCC) Actualités

CCCC

C4 Therapeutics (CCCC)

C4 Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CCCC
DateHeureSourceTitreSymboleSociété
11/06/202422h46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CCCCC4 Therapeutics Inc
11/06/202422h45Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CCCCC4 Therapeutics Inc
10/06/202413h41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CCCCC4 Therapeutics Inc
10/06/202413h00GlobeNewswire Inc.C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of DirectorsNASDAQ:CCCCC4 Therapeutics Inc
08/05/202413h10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CCCCC4 Therapeutics Inc
08/05/202413h00GlobeNewswire Inc.C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:CCCCC4 Therapeutics Inc
29/04/202422h01GlobeNewswire Inc.C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:CCCCC4 Therapeutics Inc
09/04/202413h00GlobeNewswire Inc.C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology ForumNASDAQ:CCCCC4 Therapeutics Inc
08/04/202414h00GlobeNewswire Inc.C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024NASDAQ:CCCCC4 Therapeutics Inc
05/03/202422h30GlobeNewswire Inc.C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024NASDAQ:CCCCC4 Therapeutics Inc
04/03/202413h00GlobeNewswire Inc.C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic ProteinsNASDAQ:CCCCC4 Therapeutics Inc
22/02/202415h01Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CCCCC4 Therapeutics Inc
22/02/202413h20Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CCCCC4 Therapeutics Inc
22/02/202413h00GlobeNewswire Inc.C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:CCCCC4 Therapeutics Inc
14/02/202415h21Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CCCCC4 Therapeutics Inc
05/02/202416h24Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CCCCC4 Therapeutics Inc
09/01/202422h01GlobeNewswire Inc.C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation MedicinesNASDAQ:CCCCC4 Therapeutics Inc
04/01/202422h01GlobeNewswire Inc.C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta PharmaceuticalsNASDAQ:CCCCC4 Therapeutics Inc
04/01/202413h00GlobeNewswire Inc.C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:CCCCC4 Therapeutics Inc
12/12/202322h01GlobeNewswire Inc.C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple MyelomaNASDAQ:CCCCC4 Therapeutics Inc
12/12/202315h15AllPennyStocks.comBiotech Catches Major Premarket BidNASDAQ:CCCCC4 Therapeutics Inc
12/12/202313h00GlobeNewswire Inc.C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)NASDAQ:CCCCC4 Therapeutics Inc
28/11/202313h00GlobeNewswire Inc.C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple MyelomaNASDAQ:CCCCC4 Therapeutics Inc
20/11/202313h00GlobeNewswire Inc.C4 Therapeutics Strengthens Board of Directors with Owen Hughes AppointmentNASDAQ:CCCCC4 Therapeutics Inc
01/11/202312h00GlobeNewswire Inc.C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:CCCCC4 Therapeutics Inc
11/10/202313h00GlobeNewswire Inc.C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple MyeNASDAQ:CCCCC4 Therapeutics Inc
05/09/202322h01GlobeNewswire Inc.C4 Therapeutics Announces Chief Financial Officer SuccessionNASDAQ:CCCCC4 Therapeutics Inc
08/08/202313h00GlobeNewswire Inc.C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:CCCCC4 Therapeutics Inc
17/07/202313h00GlobeNewswire Inc.C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:CCCCC4 Therapeutics Inc
05/07/202316h30Dow Jones NewsC4 Therapeutics Shares Up 18% After Lung Cancer Drug Application Receives FDA ClearanceNASDAQ:CCCCC4 Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CCCC

Dernières Valeurs Consultées

BIT
P1Y1L8
NLBNPIT1Y1L8 20240621 100
BIT
P1V983
NLBNPIT1V983 20351221 17...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés